Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
COLUMN
How Manufacturers Can Optimize Wholesaler Relationships and Leverage Wholesalers to Support Business Strategy
Biopharmaceutical wholesalers in Japan play broader roles than their counterparts overseas. Beyond logistics and distribution, wholesalers perform a variety of tasks related to finance, safety, and commercialization. Such functions are typically cited as justification for various fees, rebates, and allowances…
To read the full story
COLUMN
- Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
March 27, 2026
- The Strategic MSL: Beyond Data Delivery, It’s About Impact
February 19, 2026
- AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential
January 27, 2026
- AI: Your New HR BFF (Not Your Replacement!)
December 24, 2025
- AI in HR: Navigating the Ethical Minefield
November 28, 2025
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…